Nasus Pharma (NSRX) Stock Price, Quote, News & History

Nasus Pharma Ltd (NSRX) Stock Price, Quote, News & History

NSRXAMEX

Trade with Public

$2.00

-0.01-0.50%

Last update: Mar 31, 8:53 AM

Key Statistics

Open

$2.05

Volume / Avg.

15.21K / 165.00K

Day Range

$1.98 - $2.05

52 Wk Range

2.00 - 9.99

Market Cap

$23.42M

P/E Ratio

Dividend Yield

Exchange

AMEX

RSI

Short Interest

0.17%

Days to Cover

2.72

Recent Nasus Pharma Ltd News

What's Going On With Nasus Pharma Stock On Wednesday

Nasus Pharma stock drops despite fast NS002 results beating EpiPen. Here's why shares are falling and what the data shows.

Vandana Singh

Nasus Pharma Stock Hits 52-Week Low - Here's Why

Nasus Pharma (NSRX) hits a 52-week low despite positive Phase 2 data for its EpiPen rival. See why the stock is down 43% today.

Vandana Singh

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-4.92M

Investing Cash Flow (TTM)

-3.01M

Financing Cash Flow (TTM)

8.92M

Free Cash Flow (TTM)

-4.93M

Capital Expenditure (TTM)

-14.00K

Net Change in Cash (TTM)

988.00K

Analyst Trends and Forecast

Dec 25

Mar

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.5

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$19.37M

PE Ratio (TTM)

PE Ratio (FWD)

PEG Ratio (TTM)

PS Ratio (TTM)

PB Ratio (TTM)

8.50

Earnings Yield % (TTM)

-36.06%

Earnings Yield % (FWD)

EV / EBITDA (TTM)

Price / EBITDA (TTM)

Price / Free Cash Flow (TTM)

Book Value / Share

$0.24

Company Debt

Total Debt

LT Debt

LT Debt Issuance (TTM)

LT Debt Repayment (TTM)

Total Cash

$1.24M

Debt to Equity

0.04

Issuance of Debt (TTM)

Repayment of Debt (TTM)

Key Statistics

Open

$2.05

Volume / Avg.

15.21K / 165.00K

Day Range

$1.98 - $2.05

52 Wk Range

2.00 - 9.99

Market Cap

$23.42M

P/E Ratio

Dividend Yield

Exchange

AMEX

RSI

Short Interest

0.17%

Days to Cover

2.72

About

Sector

Health Care

Industry

Pharmaceuticals

Nasus Pharma Ltd is a clinical-stage specialty pharmaceutical company focused principally on the development of intranasal drugs to treat emergency medical conditions. It is engaged in developing a number of intranasal powder products based on its a ...

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

How do I buy Nasus Pharma (NSRX) stock?

You can purchase shares of Nasus Pharma (AMEX:NSRX) through any online brokerage.

View our list of the best stock brokerages

Who are Nasus Pharma (NSRX) competitors?

Other companies in Nasus Pharma’s space includes: Cocrystal Pharma Inc (NASDAQ:COCP), SCYNEXIS Inc (NASDAQ:SCYX), VYNE Therapeutics Inc (NASDAQ:VYNE), Telomir Pharmaceuticals Inc (NASDAQ:TELO) and Tvardi Therapeutics Inc (NASDAQ:TVRD).

What is the forecast, or price target, for Nasus Pharma (NSRX) stock?

Nasus Pharma has a consensus price target of $19.67.

What is the current price for Nasus Pharma (NSRX)?

The stock price for Nasus Pharma (AMEX: NSRX) is $2 last updated March 31, 2026 at 8:53 AM EDT.

Does Nasus Pharma (NSRX) pay a dividend?

There are no upcoming dividends for Nasus Pharma.

When is Nasus Pharma (AMEX:NSRX) reporting earnings?

Nasus Pharma does not have any upcoming earnings scheduled.

Is Nasus Pharma (NSRX) going to split?

There is no upcoming split for Nasus Pharma.

What sector and industry does Nasus Pharma (NSRX) operate in?

Nasus Pharma is in the Health Care sector and Pharmaceuticals industry. They are listed on the AMEX.

People Also Watch

VYNE Therapeutics Inc

NASDAQ:VYNE

$0.60

0.34%

Telomir Pharmaceuticals Inc

NASDAQ:TELO

$1.17

5.26%

Tvardi Therapeutics Inc

Cadrenal Therapeutics Inc

Key Statistics

Open

$2.05

Volume / Avg.

15.21K / 165.00K

Day Range

$1.98 - $2.05

52 Wk Range

2.00 - 9.99

Market Cap

$23.42M

P/E Ratio

Dividend Yield

Exchange

AMEX

RSI

Short Interest

0.17%

Days to Cover

2.72

Recent Nasus Pharma Ltd News

What's Going On With Nasus Pharma Stock On Wednesday

Nasus Pharma stock drops despite fast NS002 results beating EpiPen. Here's why shares are falling and what the data shows.

Vandana Singh

Nasus Pharma Stock Hits 52-Week Low - Here's Why

Nasus Pharma (NSRX) hits a 52-week low despite positive Phase 2 data for its EpiPen rival. See why the stock is down 43% today.

Vandana Singh

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-4.92M

Investing Cash Flow (TTM)

-3.01M

Financing Cash Flow (TTM)

8.92M

Free Cash Flow (TTM)

-4.93M

Capital Expenditure (TTM)

-14.00K

Net Change in Cash (TTM)

988.00K

Analyst Trends and Forecast

Dec 25

Mar

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.5

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$19.37M

PE Ratio (TTM)

PE Ratio (FWD)

PEG Ratio (TTM)

PS Ratio (TTM)

PB Ratio (TTM)

8.50

Earnings Yield % (TTM)

-36.06%

Earnings Yield % (FWD)

EV / EBITDA (TTM)

Price / EBITDA (TTM)

Price / Free Cash Flow (TTM)

Book Value / Share

$0.24

Company Debt

Total Debt

LT Debt

LT Debt Issuance (TTM)

LT Debt Repayment (TTM)

Total Cash

$1.24M

Debt to Equity

0.04

Issuance of Debt (TTM)

Repayment of Debt (TTM)

Key Statistics

Open

$2.05

Volume / Avg.

15.21K / 165.00K

Day Range

$1.98 - $2.05

52 Wk Range

2.00 - 9.99

Market Cap

$23.42M

P/E Ratio

Dividend Yield

Exchange

AMEX

RSI

Short Interest

0.17%

Days to Cover

2.72

About

Sector

Health Care

Industry

Pharmaceuticals

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry